/DNLI
DNLI Stock - Denali Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$16.85+0.48%
+$0.08 (+0.48%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+93.9%upside
Target: $32.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DNLI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.68 – $17.02
TARGET (TP)$32.67
STOP LOSS$15.50
RISK/REWARD1:11.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$24.34
52W Low$10.57
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $330.53M | $108.46M | $48.66M | $335.66M |
| Gross Profit | N/A | $330.53M | $108.46M | $48.66M | $123.04M |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 36.7% |
| Operating Income | $-487,341,000 | $-196,699,000 | $-340,744,000 | $-295,751,000 | $62.72M |
| Net Income | $-422,773,000 | $-145,224,000 | $-325,991,000 | $-290,581,000 | $71.14M |
| Net Margin | N/A | -43.9% | -300.6% | -597.2% | 21.2% |
| EPS | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.65 |
Company Overview
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
92%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish1 Neutral/Bearish
Price Targets
$36
Average Target
↑ 113.6% Upside
Now
$28
Low
$36
Average
$50
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 10th 2025 | Cantor Fitzgerald | Upgrade | Overweight | - |
| March 7th 2025 | Morgan Stanley | Resumed | Overweight | $33← $41 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $31 |
| January 7th 2025 | Robert W. Baird | Initiation | Outperform | $31 |
| January 3rd 2025 | William Blair | Initiation | Outperform | - |
| December 16th 2024 | Stifel | Upgrade | Buy | $37 |
| October 10th 2024 | Raymond James | Resumed | Market Perform | - |
| October 7th 2024 | Cantor Fitzgerald | Downgrade | Neutral | - |
| December 13th 2023 | Citigroup | Initiation | Buy | $32 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $28 |
| October 24th 2023 | Cantor Fitzgerald | Resumed | Overweight | $35← $85 |
| September 6th 2023 | B. Riley Securities | Initiation | Buy | $38 |
| January 30th 2023 | SVB Securities | Initiation | Outperform | $50 |
| December 5th 2022 | Cowen | Initiation | Outperform | - |
| November 2nd 2022 | BofA Securities | Initiation | Buy | $40 |
Earnings History & Surprises
DNLIBeat Rate
44%
Last 18 quarters
Avg Surprise
+9.8%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.74
Q4 2025
EPS Surprise History
Q1 24
-4.9%
$-0.86vs$-0.82
Q2 24
-1.5%
$-0.68vs$-0.67
Q3 24
+13.2%
$-0.59vs$-0.68
Q4 24
-5.0%
$-0.63vs$-0.60
Q1 25
+10.7%
$-0.67vs$-0.75
Q2 25
-9.9%
$-0.78vs$-0.71
Q3 25
+2.7%
$-0.72vs$-0.74
Q4 25
+2.6%
$-0.74vs$-0.76
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.76 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.76 | $-0.74 | +2.6% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.74 | $-0.72 | +2.7% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.71 | $-0.78 | -9.9% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.75 | $-0.67 | +10.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.60 | $-0.63 | -5.0% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.68 | $-0.59 | +13.2% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.67 | $-0.68 | -1.5% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.82 | $-0.86 | -4.9% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.83 | $-0.72 | +13.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.68 | $1.30 | +291.2% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.71 | $-0.80 | -12.7% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-0.78 | $-0.75 | +3.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.83 | $-0.84 | -1.2% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.47 | $-0.53 | -12.8% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.41 | $-0.62 | -51.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.51 | $-0.69 | -35.3% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.37 | $-0.50 | -35.1% | ✗ MISS |
Latest News
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
➖ NeutralBenzinga•Dec 11, 2025, 02:31 PM
Denali Therapeutics shares are trading lower after the company announced the pricing of its $200 million offering of 9.14 million shares at $17.50.
📉 NegativeBenzinga•Dec 10, 2025, 01:46 PM
Denali Therapeutics prices stock offering at $17.50 per share
➖ NeutralSeeking Alpha•Dec 10, 2025, 07:50 AM
Denali Therapeutics Prices Public Offering Of 9.14M Shares At $17.50 And 2.29M Pre-Funded Warrants, Targeting ~$200M Gross Proceeds
➖ NeutralBenzinga•Dec 10, 2025, 07:00 AM
Denali Therapeutics shares are trading lower after the company announced a $200 million proposed offering of common stock and pre-funded warrants.
📉 NegativeBenzinga•Dec 9, 2025, 09:21 PM
Denali Therapeutics Announces $200M Proposed Offering Of Common Stock And Pre-Funded Warrants
➖ NeutralBenzinga•Dec 9, 2025, 09:02 PM
Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $31
📈 PositiveBenzinga•Dec 5, 2025, 01:40 PM
BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
📈 PositiveBenzinga•Dec 5, 2025, 10:37 AM
Denali Therapeutics shares are trading higher after the company and Royalty Pharma announced a $275 million synthetic royalty funding agreement.
📈 PositiveBenzinga•Dec 4, 2025, 06:14 PM•Also:
Denali Therapeutics And Royalty Pharma Announce $275M Synthetic Royalty Funding Agreement Based On Future Net Sales Of Tividenofusp Alfa
📈 PositiveBenzinga•Dec 4, 2025, 12:05 PM•Also:
Denali Therapeutics Q3 EPS $(0.74) Beats $(0.75) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:58 PM
JP Morgan Maintains Overweight on Denali Therapeutics, Raises Price Target to $26
📈 PositiveBenzinga•Nov 4, 2025, 03:00 PM
Denali Therapeutics Announces FDA Extends The Review Timeline For Its Biologics License Application For Tividenofusp Alfa, A Potential Treatment For Hunter Syndrome
➖ NeutralBenzinga•Oct 13, 2025, 08:03 PM
Cantor Fitzgerald Reiterates Overweight on Denali Therapeuticsto Overweight
📈 PositiveBenzinga•Sep 8, 2025, 01:20 PM
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $30
➖ NeutralBenzinga•Aug 18, 2025, 01:17 PM
Frequently Asked Questions about DNLI
What is DNLI's current stock price?
Denali Therapeutics Inc. (DNLI) is currently trading at $16.85 per share. The stock has moved +0.48% today.
What is the analyst price target for DNLI?
The average analyst price target for DNLI is $32.67, based on 1 analyst.
What sector is Denali Therapeutics Inc. in?
Denali Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DNLI's market cap?
Denali Therapeutics Inc. has a market capitalization of $2.47 billion, making it a mid-cap company.
Does DNLI pay dividends?
No, Denali Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to DNLI for comparison